The biotech has won approval for one of the few gene-editing therapies on the market. Several more therapies based on the same science are in the works. Like most young biopharma companies, this one ...

As he addressed an audience of virologists from China, Australia, and Singapore at October’s Pandemic Research Alliance Symposium, Wei Zhao introduced an eye-catching idea. The gene-editing technology ...

A new review finds CRISPR engineering can sharply raise carotenoid yields in microalgae, yet these gains mostly redistribute ...

CRISPR Therapeutics and Vertex Pharmaceuticals have noted that the medicine currently has an addressable market of roughly 60 ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Deep-pocketed investors have adopted a bearish approach towards CRISPR Therapeutics (NASDAQ:CRSP), and it's something market players shouldn't ignore. Our tracking of public options records at ...

Don't read too much into this year's lackluster performance. Near-term catalysts are firming up.

Crispr Therapeutics AG remains a Strong Buy, driven by forthcoming revenue following Casgevy's FDA/EMA approvals and a robust, expanding pipeline targeting high-value indications. CRSP's commercial ...

Whales with a lot of money to spend have taken a noticeably bearish stance on CRISPR Therapeutics. Looking at options history for CRISPR Therapeutics (NASDAQ:CRSP) we detected 13 trades. If we ...

HHS unveiled a new Alzheimer's and dementia plan in Fort Lauderdale focused on prevention and early detection. Here is what is promised and proven. Final CDC Data Put U.S. Fertility Rate at Record Low ...

CRISPR Therapeutics has seen its share price under pressure in recent years, even as fresh clinical data like the planned CTX310 presentation in November 2026 keeps interest in its gene editing ...